News

 

 

Funding: New Awards

Richard J. Barth
Associate Professor
Immunology and Cancer Immunotherapy

  • PI/Dept Funding
    A randomized Phase II study of the effect of a low calorie diet on patients undergoing liver resection

Alexey V. Danilov
Visiting Scientist
Molecular Therapeutics

  • Sanofi-Aventis
    A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma

Marc S. Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • SWOG
    EVEREST:  EVErolimus for renal cancer ensuing surgical therapy, a Phase III study

Camilo E. Fadul
Professor
Immunology and Cancer Immunotherapy

  • Celldex
    An international, randomized, double-blind, controlled study of rindopepimut/GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma (The “ACT IV” Study)

Peter A. Kaufman
Associate Professor
Molecular Therapeutics

  • Roche Laboratories
    A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer

Frederick Lansigan
Assistant Professor
Molecular Therapeutics

  • Yale Cancer Center
    A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients

James R. Rigas
Associate Professor
Molecular Therapeutics

  • Genentech
    A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance tarceva vs tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy